Flashpoint Therapeutics logo — Pioneering a novel approach to cancer immunotherapies that c...

Flashpoint Therapeutics

Pioneering a novel approach to cancer immunotherapies that convert therapeutic elements from ineffective to curative.

Founded 2022 2-10 employees Seed Total: $10.00M Health and Wellness

General Information

Company Name Flashpoint Therapeutics
Founded Year 2022
Employees 2-10
Industries Health and Wellness
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Flashpoint Therapeutics. To contact Flashpoint Therapeutics, visit flashpoint.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Flashpoint Therapeutics compare?

A PDF of Flashpoint Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Flashpoint Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Flashpoint Therapeutics

Flashpoint Therapeutics is a pioneering cancer immunotherapy startup founded in 2022. With the slogan "Pioneering a novel approach to cancer immunotherapies that convert therapeutic elements from ineffective to curative," the company is introducing a groundbreaking method for developing cancer immunotherapies. Flashpoint Therapeutics recently secured a significant $10.00M in Seed Round investment on 25 October 2023 from prominent investors including Beta Lab and CS Venture Opportunities Fund. The startup aims to revolutionize cancer treatment by transforming therapeutic components from ineffective to curative, marking an innovative stride in the field of oncology.

Business keywords: cancer immunotherapies, novel approach, therapeutic elements, curative treatments, medical innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $10.00M 2
Beta Lab, CS Venture Opportunities Fund
25 Oct 2023

Flashpoint Therapeutics Alternatives & Competitors

View All Alternatives
Flashpoint Therapeutics vs

Multi-specific antibodies that enable the pursuit of novel therapeutic strategies.

Series C
68 employees
Biopharma, Biotechnology
Flashpoint Therapeutics vs

Improving the lives of #patients with #cancer through the #development and improvement of #therapeut...

Series A
2 employees
Biotechnology, Health and Wellness
Flashpoint Therapeutics vs

At Puma Biotechnology, our focus is on bringing innovative therapies to patients to enhance cancer c...

Post-IPO Equity
244 employees
Biotechnology, Health and Wellness

FAQ About Flashpoint Therapeutics

Pioneering a novel approach to cancer immunotherapies that convert therapeutic elements from ineffective to curative.
Flashpoint Therapeutics was founded in 2022.
Flashpoint Therapeutics operates in Health and Wellness. Its work centres on cancer immunotherapies, novel approach, therapeutic elements and curative treatments.
Flashpoint Therapeutics has approximately 2-10 employees.
Flashpoint Therapeutics has completed 1 funding round, raising a total of $10.00M. The latest funding stage is Seed.
Top alternatives and competitors to Flashpoint Therapeutics include Numab Therapeutics AG, Kirilys Therapeutics, Puma Biotechnology, Inc., Exalys Therapeutics, Kelonia Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Flashpoint Therapeutics and Numab Therapeutics AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Flashpoint Therapeutics, https://bouncewatch.com/company/flashpoint-therapeutics, updated 11 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes